Sugi Predict

Sugi Predict / Targets / DYRK4

DYRK4

Dual specificity tyrosine-phosphorylation-regulated kinase 4 · Q9NR20 · DYRK4 on Sugi Atlas →

12,835 patent compounds predicted against DYRK4, 9,403 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL513882 SCHEMBL513882 0.46 15/20
SCHEMBL1418925 SCHEMBL1418925 0.46 12/20
SCHEMBL513237 SCHEMBL513237 0.41 6/20
Benzo[D]Thiazole Benzo[D]Thiazole (SCHEMBL544175) 0.34 6/20
SCHEMBL1043587 SCHEMBL1043587 0.77 4/20
SCHEMBL1046067 SCHEMBL1046067 0.72 4/20
SCHEMBL1043445 SCHEMBL1043445 0.67 4/20
SCHEMBL1043448 SCHEMBL1043448 0.67 4/20
SCHEMBL1045877 SCHEMBL1045877 0.65 4/20
SCHEMBL1045231 SCHEMBL1045231 0.63 4/20
SCHEMBL1045663 SCHEMBL1045663 0.62 4/20
SCHEMBL1044969 SCHEMBL1044969 0.60 4/20
SCHEMBL1046432 SCHEMBL1046432 0.59 4/20
SCHEMBL1044761 SCHEMBL1044761 0.58 4/20
SCHEMBL1041773 SCHEMBL1041773 0.56 4/20
SCHEMBL1046029 SCHEMBL1046029 0.55 4/20
SCHEMBL1045731 SCHEMBL1045731 0.51 4/20
SCHEMBL1046261 SCHEMBL1046261 0.50 4/20
SCHEMBL1133482 SCHEMBL1133482 1.00 3/20
SCHEMBL1133999 SCHEMBL1133999 1.00 3/20

Clinical trials — most relevant to DYRK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial PHASE4NOT_YET_RECRUITING
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer PHASE4RECRUITING
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer PHASE3UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer PHASE2RECRUITING
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer PHASE2COMPLETED
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer PHASE2UNKNOWN
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors PHASE1COMPLETED
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy nanUNKNOWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DYRK4 binder may also engage these)

ProteinNameSimilarity
Q8BI55 — 0.997 Q8BI55 →
Q4V8A3 — 0.997 Q4V8A3 →
O70551 — 0.994 O70551 →
DYRK3 Dual specificity tyrosine-phosphorylation-regulated kinase 3 0.994 landscape →
Q922Y0 — 0.993 Q922Y0 →
Q4R6S5 — 0.992 Q4R6S5 →
Q8VZD5 — 0.992 Q8VZD5 →
Q5RD27 — 0.991 Q5RD27 →
Q6Z8C8 — 0.990 Q6Z8C8 →
P51138 — 0.990 P51138 →
Q96287 — 0.990 Q96287 →
Q91VB2 — 0.990 Q91VB2 →
SRPK1 SRSF protein kinase 1 0.989 landscape →
P43289 — 0.989 P43289 →
A5GFW1 — 0.989 A5GFW1 →
Q5VP69 — 0.988 Q5VP69 →
O23145 — 0.988 O23145 →
P43294 — 0.988 P43294 →
Q5XIT0 — 0.988 Q5XIT0 →
C0RW22 — 0.987 C0RW22 →
Q9FVS6 — 0.987 Q9FVS6 →
Q6YY75 — 0.987 Q6YY75 →
B2GUY1 — 0.987 B2GUY1 →
P97477 — 0.987 P97477 →
P43288 — 0.987 P43288 →
P13234 — 0.987 P13234 →
Q5R667 — 0.987 Q5R667 →
Q5SN53 — 0.987 Q5SN53 →
CDKL4 Cyclin-dependent kinase-like 4 0.987 landscape →
Q63553 — 0.986 Q63553 →